Inequality and poor planning have marred the U.S. response to Covid-19. The same can’t happen for new therapies like the one just approved from Eli Lilly.
Inequality and poor planning have marred the U.S. response to Covid-19. The same can’t happen for new therapies like the one just approved from Eli Lilly.